Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
300 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glaucoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Glaucoma - Pipeline Review, H2 2015', provides an overview of the Glaucoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Glaucoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Glaucoma Overview 11 Therapeutics Development 12 Pipeline Products for Glaucoma - Overview 12 Pipeline Products for Glaucoma - Comparative Analysis 13 Glaucoma - Therapeutics under Development by Companies 14 Glaucoma - Therapeutics under Investigation by Universities/Institutes 20 Glaucoma - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Glaucoma - Products under Development by Companies 25 Glaucoma - Products under Investigation by Universities/Institutes 32 Glaucoma - Companies Involved in Therapeutics Development 33 AC Immune SA 33 Acadia Pharmaceuticals Inc. 34 Advanced Refractive Technologies, Inc. 35 Aerie Pharmaceuticals, Inc. 36 Allergan Plc 37 Altacor Limited 38 Amakem NV 39 Asahi Kasei Pharma Corp. 40 AUS Bio Limited 41 Bausch & Lomb Incorporated 42 Bionure Farma, S.L. 43 Caladrius Biosciences, Inc. 44 Can-Fite BioPharma Ltd. 45 China Grand Wuhan General Pharmaceutical Research Institute 46 D. Western Therapeutics Institute, Inc. 47 DNAVEC Corporation 48 Dompe Farmaceutici S.p.A. 49 F. Hoffmann-La Roche Ltd. 50 Gene Signal International SA 51 Gilead Sciences, Inc. 52 Glaukos Corporation 53 GliaCure Inc. 54 Handok Inc. 55 Icon Bioscience, Inc. 56 IMMD Inc. 57 InMed Pharmaceuticals Inc. 58 Inotek Pharmaceuticals Corporation 59 InSite Vision Incorporated 60 Kadmon Corporation, LLC 61 Kala Pharmaceuticals, Inc. 62 Kukje Pharmaceutical Industry Co., Ltd. 63 Lacer, S.A. 64 Lee's Pharmaceutical Holdings Limited 65 Merck & Co., Inc. 66 Merz Pharma GmbH & Co. KgaA 67 Neurotech Pharmaceuticals, Inc. 68 NicOx S.A. 69 NoNO, Inc. 70 Ocata Therapeutics, Inc. 71 Ocular Therapeutix, Inc. 72 Oculis ehf 73 Ohr Pharmaceutical Inc. 74 Ono Pharmaceutical Co., Ltd. 75 Otsuka Holdings Co., Ltd. 76 Oxford BioMedica Plc 77 Quark Pharmaceuticals, Inc. 78 Quethera Limited 79 Regeneron Pharmaceuticals, Inc. 80 Sanofi 81 Santen Pharmaceutical Co., Ltd. 82 Senju Pharmaceutical Co., Ltd. 83 Shire Plc 84 SK Biopharmaceuticals Co., Ltd. 85 Sun Pharma Advanced Research Company Ltd. 86 Sylentis S.A. 87 ViSci Ltd. 88 vTv Therapeutics LLC 89 Glaucoma - Therapeutics Assessment 90 Assessment by Monotherapy Products 90 Assessment by Combination Products 91 Assessment by Target 92 Assessment by Mechanism of Action 97 Assessment by Route of Administration 101 Assessment by Molecule Type 103 Drug Profiles 105 (bimatoprost + brimonidine tartrate) - Drug Profile 105 (carteolol hydrochloride + latanoprost) - Drug Profile 106 (dorzolamide hydrochloride + latanoprost) - Drug Profile 107 (latanoprost + netarsudil mesylate) - Drug Profile 108 (latanoprost + trabodenoson) - Drug Profile 109 (tafluprost + timolol maleate) - Drug Profile 110 AC-262271 - Drug Profile 111 ACI-260 - Drug Profile 112 ACN-1052 - Drug Profile 113 aflibercept - Drug Profile 114 aganirsen - Drug Profile 117 ALT-022 - Drug Profile 119 ALY-1337 - Drug Profile 120 AMA-0076 - Drug Profile 121 Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 122 Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile 123 APH-1104 - Drug Profile 124 AR-13324 - Drug Profile 125 AR-13533 - Drug Profile 126 ATS-8535 - Drug Profile 127 BA-1049 - Drug Profile 128 BA-240 - Drug Profile 129 bamosiran - Drug Profile 130 bimatoprost - Drug Profile 132 bimatoprost - Drug Profile 133 bimatoprost SR - Drug Profile 134 BN-201 - Drug Profile 135 brimonidine tartrate - Drug Profile 136 CTI-085 - Drug Profile 137 DE-117 - Drug Profile 138 decorin - Drug Profile 139 Drug for Glaucoma - Drug Profile 140 Drug for Glaucoma - Drug Profile 141 Drugs for Steroid Induced Glaucoma - Drug Profile 142 Drugs to Inhibit Cadherin-5 for Glaucoma - Drug Profile 143 Drugs to Target Bestrophin-2 for Glaucoma - Drug Profile 144 GB-201 - Drug Profile 145 GB-202 - Drug Profile 146 GB-203 - Drug Profile 147 GB-204 - Drug Profile 148 GC-021109 - Drug Profile 149 Gene Therapy for Glaucoma - Drug Profile 150 Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 151 Gene Therapy for Ocular Diseases - Drug Profile 152 Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 153 Glaucoma-GT - Drug Profile 154 GS-607601 - Drug Profile 155 H-1129 - Drug Profile 156 HL-3501 - Drug Profile 157 HPP-851 - Drug Profile 158 IMD-1041 - Drug Profile 159 KJ-13003 - Drug Profile 160 KJ-14002 - Drug Profile 161 KL-00199 - Drug Profile 162 KR-12 - Drug Profile 163 LA-8045 - Drug Profile 164 latanoprost - Drug Profile 165 latanoprost - Drug Profile 166 latanoprost - Drug Profile 168 latanoprost - Drug Profile 169 latanoprost SR - Drug Profile 170 latanoprost SR - Drug Profile 172 latanoprostene bunod - Drug Profile 173 levobetaxolol hydrochloride - Drug Profile 175 lomerizine - Drug Profile 176 MD-920G - Drug Profile 177 MRZ-99030 - Drug Profile 178 NB-1111 - Drug Profile 179 NCX-1021 - Drug Profile 181 NCX-250 - Drug Profile 182 NCX-470 - Drug Profile 183 NCX-667 - Drug Profile 184 neurovitas - Drug Profile 185 NT-501 - Drug Profile 186 OC-201 - Drug Profile 189 OC-410 - Drug Profile 190 ONO-9054 - Drug Profile 191 OPA-6566 - Drug Profile 192 PBF-677 - Drug Profile 193 piclidenoson - Drug Profile 194 QPI-1007 - Drug Profile 196 R-801 - Drug Profile 198 R-807 - Drug Profile 200 Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 201 RO-5093151 - Drug Profile 203 SAR-366234 - Drug Profile 204 SHP-639 - Drug Profile 205 SKL-G - Drug Profile 206 Small Molecule for Glaucoma - Drug Profile 207 Small Molecule to Agonize 5HT2 for Glaucoma - Drug Profile 208 Small Molecule to Inhibit Amyloid Beta for Glaucoma and Dry AMD - Drug Profile 209 Small Molecule to Inhibit Rho Kinase for Glaucoma - Drug Profile 210 Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 211 Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 212 Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile 213 Small Molecules to Antagonize CXCR3 for Glaucoma - Drug Profile 214 Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 215 Small Molecules to Antagonize TRPV4 for Glaucoma - Drug Profile 216 Small Molecules to Inhibit Dual Leucine Zipper Kinase for Glaucoma and Neurodegenerative Disorders - Drug Profile 217 Small Molecules to Inhibit LIMK1 AND LIMK2 for Cancer and Ophthalmology - Drug Profile 218 SNC-121 - Drug Profile 219 SNJ-1656 - Drug Profile 220 SNJ-1945 - Drug Profile 222 Stem Cell Therapy for Glaucoma - Drug Profile 223 Stem Cell Therapy for Macular Degeneration and Glaucoma - Drug Profile 224 Synthetic Peptide for Glaucoma - Drug Profile 225 TG-46 - Drug Profile 226 trabodenoson - Drug Profile 227 travoprost - Drug Profile 228 travoprost SR - Drug Profile 229 travoprost XR - Drug Profile 231 TRV-32R - Drug Profile 232 UM-5050 - Drug Profile 233 XY-0811QF2 - Drug Profile 234 XY-1303LT2 - Drug Profile 235 Glaucoma - Recent Pipeline Updates 236 Glaucoma - Dormant Projects 274 Glaucoma - Discontinued Products 281 Glaucoma - Product Development Milestones 283 Featured News & Press Releases 283 Appendix 291 Methodology 291 Coverage 291 Secondary Research 291 Primary Research 291 Expert Panel Validation 291 Contact Us 291 Disclaimer 292
List of Tables
Number of Products under Development for Glaucoma, H2 2015 20 Number of Products under Development for Glaucoma - Comparative Analysis, H2 2015 21 Number of Products under Development by Companies, H2 2015 23 Number of Products under Development by Companies, H2 2015 (Contd..1) 24 Number of Products under Development by Companies, H2 2015 (Contd..2) 25 Number of Products under Development by Companies, H2 2015 (Contd..3) 26 Number of Products under Development by Companies, H2 2015 (Contd..4) 27 Number of Products under Investigation by Universities/Institutes, H2 2015 28 Comparative Analysis by Late Stage Development, H2 2015 29 Comparative Analysis by Clinical Stage Development, H2 2015 30 Comparative Analysis by Early Stage Development, H2 2015 31 Comparative Analysis by Unknown Stage Development, H2 2015 32 Products under Development by Companies, H2 2015 33 Products under Development by Companies, H2 2015 (Contd..1) 34 Products under Development by Companies, H2 2015 (Contd..2) 35 Products under Development by Companies, H2 2015 (Contd..3) 36 Products under Development by Companies, H2 2015 (Contd..4) 37 Products under Development by Companies, H2 2015 (Contd..5) 38 Products under Development by Companies, H2 2015 (Contd..6) 39 Products under Investigation by Universities/Institutes, H2 2015 40 Glaucoma - Pipeline by AC Immune SA, H2 2015 41 Glaucoma - Pipeline by Acadia Pharmaceuticals Inc., H2 2015 42 Glaucoma - Pipeline by Advanced Refractive Technologies, Inc., H2 2015 43 Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2015 44 Glaucoma - Pipeline by Allergan Plc, H2 2015 45 Glaucoma - Pipeline by Altacor Limited, H2 2015 46 Glaucoma - Pipeline by Amakem NV, H2 2015 47 Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H2 2015 48 Glaucoma - Pipeline by AUS Bio Limited, H2 2015 49 Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2015 50 Glaucoma - Pipeline by Bionure Farma, S.L., H2 2015 51 Glaucoma - Pipeline by Caladrius Biosciences, Inc. , H2 2015 52 Glaucoma - Pipeline by Can-Fite BioPharma Ltd., H2 2015 53 Glaucoma - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H2 2015 54 Glaucoma - Pipeline by D. Western Therapeutics Institute, Inc., H2 2015 55 Glaucoma - Pipeline by DNAVEC Corporation, H2 2015 56 Glaucoma - Pipeline by Dompe Farmaceutici S.p.A., H2 2015 57 Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 58 Glaucoma - Pipeline by Gene Signal International SA, H2 2015 59 Glaucoma - Pipeline by Gilead Sciences, Inc., H2 2015 60 Glaucoma - Pipeline by Glaukos Corporation, H2 2015 61 Glaucoma - Pipeline by GliaCure Inc., H2 2015 62 Glaucoma - Pipeline by Handok Inc., H2 2015 63 Glaucoma - Pipeline by Icon Bioscience, Inc., H2 2015 64 Glaucoma - Pipeline by IMMD Inc., H2 2015 65 Glaucoma - Pipeline by InMed Pharmaceuticals Inc., H2 2015 66 Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2015 67 Glaucoma - Pipeline by InSite Vision Incorporated, H2 2015 68 Glaucoma - Pipeline by Kadmon Corporation, LLC, H2 2015 69 Glaucoma - Pipeline by Kala Pharmaceuticals, Inc., H2 2015 70 Glaucoma - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2015 71 Glaucoma - Pipeline by Lacer, S.A., H2 2015 72 Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 73 Glaucoma - Pipeline by Merck & Co., Inc., H2 2015 74 Glaucoma - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015 75 Glaucoma - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2015 76 Glaucoma - Pipeline by NicOx S.A., H2 2015 77 Glaucoma - Pipeline by NoNO, Inc., H2 2015 78 Glaucoma - Pipeline by Ocata Therapeutics, Inc., H2 2015 79 Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2015 80 Glaucoma - Pipeline by Oculis ehf, H2 2015 81 Glaucoma - Pipeline by Ohr Pharmaceutical Inc., H2 2015 82 Glaucoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 83 Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 84 Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2015 85 Glaucoma - Pipeline by Quark Pharmaceuticals, Inc., H2 2015 86 Glaucoma - Pipeline by Quethera Limited, H2 2015 87 Glaucoma - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 88 Glaucoma - Pipeline by Sanofi, H2 2015 89 Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015 90 Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2015 91 Glaucoma - Pipeline by Shire Plc, H2 2015 92 Glaucoma - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 93 Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 94 Glaucoma - Pipeline by Sylentis S.A., H2 2015 95 Glaucoma - Pipeline by ViSci Ltd., H2 2015 96 Glaucoma - Pipeline by vTv Therapeutics LLC, H2 2015 97 Assessment by Monotherapy Products, H2 2015 98 Assessment by Combination Products, H2 2015 99 Number of Products by Stage and Target, H2 2015 101 Number of Products by Stage and Mechanism of Action, H2 2015 106 Number of Products by Stage and Route of Administration, H2 2015 110 Number of Products by Stage and Molecule Type, H2 2015 112 Glaucoma Therapeutics - Recent Pipeline Updates, H2 2015 244 Glaucoma - Dormant Projects, H2 2015 282 Glaucoma - Dormant Projects (Contd..1), H2 2015 283 Glaucoma - Dormant Projects (Contd..2), H2 2015 284 Glaucoma - Dormant Projects (Contd..3), H2 2015 285 Glaucoma - Dormant Projects (Contd..4), H2 2015 286 Glaucoma - Dormant Projects (Contd..5), H2 2015 287 Glaucoma - Dormant Projects (Contd..6), H2 2015 288 Glaucoma - Discontinued Products, H2 2015 289 Glaucoma - Discontinued Products (Contd..1), H2 2015 290
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
